Coping Strategies, Loneliness, and Resilience in Patients With Dermatosis

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Brest

About this trial

The European Society for Dermatology \& Psychiatry (ESDaP) studies the connection between the skin and the mind. Two previous studies of this type were conducted in 13 and 15 European countries, respectively. The first study assessed the psychological impact of skin diseases (anxiety, depression, sleep disorders), and the second analyzed feelings of stigma, stress, and body dysmorphic disorder (an abnormal perception of one's body).

In this study, new psychological variables will be examined: coping strategies, loneliness, and resilience.

A total of 23 centers will participate in the ESDaP3 study, located in 15 European countries (Austria, France, Germany, Hungary, Italy, North Macedonia, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Turkey, and the United Kingdom).

The aim of this study is to examine coping strategies, loneliness, and resilience among patients with a skin condition. Coping strategies refer to the various ways a person uses to manage a difficult or stressful situation. Resilience refers to a person's ability to cope with difficult situations, adapt to changes or challenges, and regain a sense of balance despite obstacles. Other factors will be assessed: sleep, anxiety and depression, and quality of life. A questionnaire will be given to your potential partner to assess the impact of the skin condition on their life at this time.

At the study's sole French site, Brest University Hospital, 250 patients with a skin condition and 125 people without a skin condition will be enrolled.

Eligibility criteria

Qualifiers

Patients with skin conditions (inflammatory, autoimmune, cancerous, or genetic skin disorders)

Controls: individuals without skin disease

Adult participant

Participant enrolled in a Social Security system or equivalent

Disqualifiers

Participants who are unable to understand the protocol

Participants under legal guardianship (guardianship, conservatorship)

Participants subject to a future protection order, family authorization, or court-ordered protection

Participants who are unable to complete the questionnaires

Trial design

Treatments tested in this trial

  • Questionnaires

Treatment groups

375 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University Hospital, Brest

Lead sponsor

University of Graz

Collaborator

Justus-Liebig University Gießen Medical Center

Collaborator

Szeged University

Collaborator

University of Skopje

Collaborator

University of Amsterdam

Collaborator

University of Stavanger

Collaborator

University of Bergen

Collaborator

Wroclaw Medical University

Collaborator

University of Rzeszow

Collaborator

Universidade do Algarve

Collaborator

Universidad de Zaragoza

Collaborator

University of La Laguna

Collaborator

Malmö University

Collaborator

Lund University

Collaborator

Karolinska Institutet

Collaborator

Sisli Hamidiye Etfal Training and Research Hospital

Collaborator

Cardiff University

Collaborator

University Hospital Muenster

Collaborator

Leiden University Medical Center

Collaborator

The Royal London Hospital, UK

Collaborator